Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection.

In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV-1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.

[1]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[2]  J. Margolick,et al.  Failure of T-cell homeostasis preceding AIDS in HIV-1 infection , 1995, Nature Medicine.

[3]  R. Moss,et al.  Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. , 1994, The Journal of infectious diseases.

[4]  T. Quinn,et al.  Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. , 1994, JAMA.

[5]  S. Buchbinder,et al.  Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts , 1994, AIDS.

[6]  J. Gatell,et al.  Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter , 1993 .

[7]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[8]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[9]  D S Stein,et al.  CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. , 1992, The Journal of infectious diseases.

[10]  N. Dubin,et al.  CD4% is the best predictor of development of AIDS in a cohort of HIV‐infected homosexual men , 1991, AIDS.

[11]  R. Gelman,et al.  Biostatistical considerations for quality assessment of immunologic measurements used in clinical and longitudinal studies. , 1989, Clinical immunology and immunopathology.

[12]  J M Taylor,et al.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. , 1989, Journal of acquired immune deficiency syndromes.

[13]  J. Levy,et al.  Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. , 1987, The Journal of infectious diseases.